Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study.
Buprenorphine
Criminal justice involvement
Depot injection
Extended-release
Opioid use disorder
Journal
Addiction science & clinical practice
ISSN: 1940-0640
Titre abrégé: Addict Sci Clin Pract
Pays: England
ID NLM: 101316917
Informations de publication
Date de publication:
29 01 2022
29 01 2022
Historique:
received:
12
08
2021
accepted:
18
01
2022
entrez:
30
1
2022
pubmed:
31
1
2022
medline:
3
2
2022
Statut:
epublish
Résumé
Extended-release buprenorphine (XRB) offers a novel approach to sustained monthly treatment for people who use opioids in criminal justice settings (CJS). This study explores the experiences of adults receiving XRB as a jail-to-community treatment. In-depth qualitative interviews were conducted among adult participants with opioid use disorder (OUD; n = 16) who were recently released from NYC jails and maintained on XRB after switching from daily sublingual buprenorphine (SLB). Interviews elaborated on the acceptability and barriers and facilitators of XRB treatment pre- and post-release. Interviews were audio recorded, transcribed, and analyzed for content related to factors influencing XRB treatment uptake and community reentry. Important themes were grouped into systems, medication, and patient-level factors. Key systems-level factors influencing initiation of XRB in jail included an alternative to perceived stigmatization and privacy concerns associated with daily in-jail SLB administration and less concerns with buprenorphine diversion. In-jail peer networks positively influenced participant adoption of XRB. XRB satisfaction was attributed to reduced in-jail clinic and medication administration visits, perceived efficacy and blockade effects upon the use of heroin/fentanyl following release, and averting the risk of criminal activities to fund opioid use. Barriers to retention included post-injection withdrawal symptoms and cravings attributed to perceived suboptimal medication dosing, injection site pain, and lack of in-jail provider information about the medication. Participants were generally favorable to XRB initiation in jail and retention post-release. Further studies are needed to address factors influencing access to XRB in criminal justice settings, including stigma, ensuring patient privacy following initiation on XRB, and patient-, provider-, and correctional staff education pertaining to XRB. Trial Registration ClinicalTrials.gov Identified: NCT03604159.
Sections du résumé
BACKGROUND
Extended-release buprenorphine (XRB) offers a novel approach to sustained monthly treatment for people who use opioids in criminal justice settings (CJS). This study explores the experiences of adults receiving XRB as a jail-to-community treatment.
METHODS AND FINDINGS
In-depth qualitative interviews were conducted among adult participants with opioid use disorder (OUD; n = 16) who were recently released from NYC jails and maintained on XRB after switching from daily sublingual buprenorphine (SLB). Interviews elaborated on the acceptability and barriers and facilitators of XRB treatment pre- and post-release. Interviews were audio recorded, transcribed, and analyzed for content related to factors influencing XRB treatment uptake and community reentry. Important themes were grouped into systems, medication, and patient-level factors. Key systems-level factors influencing initiation of XRB in jail included an alternative to perceived stigmatization and privacy concerns associated with daily in-jail SLB administration and less concerns with buprenorphine diversion. In-jail peer networks positively influenced participant adoption of XRB. XRB satisfaction was attributed to reduced in-jail clinic and medication administration visits, perceived efficacy and blockade effects upon the use of heroin/fentanyl following release, and averting the risk of criminal activities to fund opioid use. Barriers to retention included post-injection withdrawal symptoms and cravings attributed to perceived suboptimal medication dosing, injection site pain, and lack of in-jail provider information about the medication.
CONCLUSION
Participants were generally favorable to XRB initiation in jail and retention post-release. Further studies are needed to address factors influencing access to XRB in criminal justice settings, including stigma, ensuring patient privacy following initiation on XRB, and patient-, provider-, and correctional staff education pertaining to XRB. Trial Registration ClinicalTrials.gov Identified: NCT03604159.
Identifiants
pubmed: 35093164
doi: 10.1186/s13722-022-00288-4
pii: 10.1186/s13722-022-00288-4
pmc: PMC8800291
doi:
Substances chimiques
Buprenorphine
40D3SCR4GZ
Banques de données
ClinicalTrials.gov
['NCT03604159']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4Subventions
Organisme : NIDA NIH HHS
ID : U01-DA033336-05S1
Pays : United States
Organisme : NIDA NIH HHS
ID : K23DA042140-01A1
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Drug Alcohol Depend. 2020 Mar 1;208:107837
pubmed: 31951906
Addict Sci Clin Pract. 2015 Jan 16;10:2
pubmed: 25592182
Subst Use Misuse. 2018 Jan 28;53(2):330-333
pubmed: 28961017
Addiction. 2005 Nov;100(11):1584-93
pubmed: 16277621
N Engl J Med. 2007 Jan 11;356(2):157-65
pubmed: 17215533
Addict Sci Clin Pract. 2018 Dec 3;13(1):23
pubmed: 30509314
Addict Sci Clin Pract. 2019 Oct 1;14(1):37
pubmed: 31570100
JAMA Netw Open. 2018 Jul 6;1(3):e180558
pubmed: 30646016
Patient Prefer Adherence. 2018 Oct 11;12:2123-2129
pubmed: 30349206
Subst Abus. 2012;33(1):40-7
pubmed: 22263712
Drug Alcohol Depend. 2009 Jan 1;99(1-3):222-30
pubmed: 18930603
JAMA Netw Open. 2021 Sep 1;4(9):e2123032
pubmed: 34495340
Addiction. 2017 Aug;112(8):1432-1439
pubmed: 28319291
N Engl J Med. 2016 Mar 31;374(13):1232-42
pubmed: 27028913
J Subst Abuse Treat. 2021 Aug;127:108349
pubmed: 34134866
J Correct Health Care. 2017 Jan;23(1):83-87
pubmed: 28040993
J Subst Abuse Treat. 2019 Sep;104:64-71
pubmed: 31370986
Int J Law Psychiatry. 2011 Jul-Aug;34(4):249-55
pubmed: 21802731
Subst Abuse Rehabil. 2016 Apr 27;7:27-40
pubmed: 27217808
Subst Use Misuse. 2019;54(14):2409-2419
pubmed: 31429351
Harm Reduct J. 2019 Apr 3;16(1):25
pubmed: 30943990